Competing interests
Pierre, MR
M.R. reports personal fees for serving as an advisor from Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Immunocore; travel support from AstraZeneca; funds to his institution to support a study from Merck Sharp & Dohme. E.R. reports investigator-initiated trial funds (paid to the institution) by AstraZeneca, BMS, and Replimune; serves on the consultancy/advisory board for AstraZeneca, Merck, Roche, Light Chain Biosciences, Pierre Fabre; E.R. declares travel support from BMS, Hoffmann La Roche, AstraZeneca, Merck Sharp & Dohme. G.V. and E.R. received grants from the Fonds Amgen France pour la Science et l’Humain. MR and ER report funding to their institution to support a study from Janssen-Cilag. CaD received grants from AstraZeneca, Janssen, and Astellas. M.K. received funds from Roche. The remaining co-authors declare no competing interests.